Rationale: Pulmonary arterial hypertension (PAH) is a devastating disease characterized by progressive vasoconstriction and obliterative vascular remodeling that leads to right heart failure (RHF) and death. Current therapies do not target vascular remodeling and RHF, and result in only modest improvement of morbidity and mortality.
Objectives: To determine whether targeting HIF-2a (hypoxia-inducible factor-2a) with a HIF-2a-selective inhibitor could reverse PAH and RHF in various rodent PAH models.
Methods: HIF-2a and its downstream genes were evaluated in lung samples and pulmonary arterial endothelial cells and smooth muscle cells from patients with idiopathic PAH as well as various rodent PAH models. A HIF-2a-selective inhibitor was used in human lung microvascular endothelial cells and in Egln1
Tie2Cre mice, and in Sugen 5416/hypoxia-or monocrotalineexposed rats.
Measurements and Main Results: Upregulation of HIF-2a and its target genes was observed in lung tissues and isolated pulmonary arterial endothelial cells from patients with idiopathic PAH and three distinct rodent PAH models. Pharmacological inhibition of HIF-2a by the HIF-2a translation inhibitor C76 (compound 76) reduced right ventricular systolic pressure and right ventricular hypertrophy and inhibited RHF and fibrosis as well as obliterative pulmonary vascular remodeling in Egln1
Tie2Cre mice and Sugen 5416/hypoxia PAH rats. Treatment of monocrotaline-exposed PAH rats with C76 also reversed right ventricular systolic pressure, right ventricular hypertrophy, and pulmonary vascular remodeling; prevented RHF; and promoted survival.
Conclusions: These findings demonstrate that pharmacological inhibition of HIF-2a is a promising novel therapeutic strategy for the treatment of severe vascular remodeling and right heart failure in patients with PAH.
Keywords: cardiac fibrosis; hypoxia-inducible factor; obliterative vascular remodeling; pulmonary arterial hypertension; pharmacological therapy Pulmonary arterial hypertension (PAH) is characterized by excessive vasoconstriction and obliterative vascular remodeling that leads to right heart failure (RHF) and death (1) (2) (3) . The histopathological features of PAH include thickening of the medial and adventitial layers of pulmonary vasculature, and the formation of vascular occlusions and plexiform lesions (4) (5) (6) . Although significant advances have been made in understanding the pathogenesis of PAH, no effective therapy has been developed to reverse pulmonary vascular remodeling, inhibit RHF, and promote survival of patients with PAH. Current therapies mainly target the abnormalities in vasoconstriction in the prostacyclin, nitric oxide and endothelin signaling pathways, but not the obliterative vascular remodeling abnormalities. Hence, only modest improvements are achieved in PAH morbidity and mortality (7, 8) . Therefore, novel therapeutic agents are urgently needed for patients with PAH.
Both HIF-1a (hypoxia-inducible factor-1a) and HIF-2a are important regulators of the response to hypoxia in the pulmonary circulation (9, 10) . It has been demonstrated that both Hif1a 1/2 and Hif2a 1/2 mice exhibit blunted increases in right ventricular systolic pressure (RVSP) and RV hypertrophy in response to chronic hypoxia (11, 12) . Ball and colleagues showed that genetic deletion of Hif1a in smooth muscle cells (SMCs) in mice attenuated RVSP and pulmonary arterial wall thickness in response to chronic hypoxia treatment (13) . Intriguingly, RV remodeling was not affected in this model (13) . HIF2A gain-of-function mutation is associated with severe PAH in patients (14) . Mice with genetic knock-in of an activation mutation (G536W) of Hif2a also develop severe pulmonary hypertension (PH) (15) . Studies have highlighted the predominant role of HIF-2a versus HIF-1a activation in the pathogenesis of PAH (16) (17) (18) (19) . Humans and mice with a VHL (von Hippel-Lindau) gain-of-function mutation develop PH (16, 20) , whereas Vhl R200W mice are rescued by heterozygous deletion of Hif2a but not Hif1a (16) . Several groups including us demonstrated the critical role of endothelial HIF-2a but not HIF-1a activation in mediating pulmonary vascular remodeling and PH (17) (18) (19) . Notably, HIF-2a activation secondary to HIF PHD2 (prolyl hydroxylase-2) deficiency in mice (Egln1
Tie2Cre
) induced spontaneously obliterative vascular remodeling, severe PAH, and RHF, which resembles many pathological features of clinical PAH (17, 21, 22) . Other groups showed that mice lacking HIF-2a but not HIF-1a in lung endothelium were resistant to hypoxiainduced PH (19) . Taken together, these studies suggest that HIF signaling, specifically the PHD2/VHL/HIF-2a axis, is critical in regulating pulmonary vascular homeostasis.
Here we sought to determine the translational potential of targeting HIF-2a for the treatment of PAH and RHF, using a selective HIF-2a inhibitor. To the best of our knowledge, this is the first study showing that pharmacological treatment can effectively inhibit obliterative pulmonary vascular remodeling and RHF in three distinct rodent models of severe PAH. We also for the first time observed clear survival benefits in two of the three models through HIF-2a inhibition. Some of the results of these studies have been previously reported in the form of abstracts (23, 24) .
Methods

Human Samples
Human lung tissues were obtained from patients undergoing lung transplantation for idiopathic pulmonary arterial hypertension (IPAH) and from unused donor lungs. (17, 26, 27) . RVSP was measured with a 1.4F (mice) or 3.5F (rats) pressure transducer catheter (Millar Instruments) as described previously (17, (25) (26) (27) .
Human PASMC Proliferation Analysis
Human lung microvascular endothelial cells (HLMVECs) were transfected with scrambled siRNA or siRNA against PHD2, using an HMVEC-L Nucleofector kit with the Amaxa Nucleofector 2D device as described previously (17) . Forty-eight hours after transfection, HLMVECs were incubated with DMSO or C76 (20 mM) in serum-free medium for another 24 hours. Conditioned medium was collected and added to serum-starved SMCs for 16 hours. 5-Bromo-29-deoxyuridine (BrdU, 10 mM; Sigma) was added for incubation of SMCs with EC-conditioned medium. SMCs were immunostained with anti-BrdU-FITC (BD Biosciences) according to the manufacturer's instructions, and nuclei were counterstained with DAPI.
Luciferase Assays
HLMVECs were transfected with an HRELuc plasmid (Promega), or as an internal control pRL-TK plasmid, using an HMVEC-L Nucleofector kit with the Amaxa Nucleofector 2D device as described previously (17) . To activate HIF-a, cells were treated with either dimethyloxallyl glycine (DMOG, 1 mM) or cotransfected with PHD2 siRNA. For the DMOG treatment study, the cells were treated with either DMSO, HIF-2a antagonist 2 (H2A, 20 mM), or HIF-2a translation inhibitor C76 (20 mM) for 24 hours. Both firefly and Renilla luciferase activities were assessed. The values are expressed as fold change relative to the DMSO group. For the PHD2 siRNA study, at 6 hours after transfection, the cells were treated with either DMSO, H2A (20 mM), or C76 (20 mM) for 14 hours and then assessed for firefly and Renilla luciferase activities. 
Immunofluorescence Staining and Histological Assessment
Tissue processing and immunofluorescence staining were performed as described previously (17, 26) . For histological assessment, sections were stained with a Russell-Movat pentachrome staining kit (American MasterTech) or with a trichrome stain (Masson) kit (SigmaAldrich) according to the manufacturer's instructions (17) . Sections were imaged with an Aperio CS2 light microscope (Leica Biosystems).
Statistical Analysis
Statistical analysis of data was done with Prism 7 (GraphPad Software, Inc.). Statistical significance for multiple-group comparisons was determined by one-way ANOVA with Tukey post hoc analysis that calculates corrected P values. Two-group comparisons were analyzed by the unpaired two-tailed Student t test for equal variance or by Mann-Whitney test for unequal variance. Statistical analysis for the mortality study was assessed by the logrank (Mantel-Cox) test. P , 0.05 denoted the presence of a statistically significant difference. All bar graphs represent means 6 SD. Bars in dot plot figures represent the mean.
Detailed materials and methods are available in the online supplement.
Results
Activation of HIF-2a in Patients with IPAH and Three PAH Rodent Models
We first determined whether HIF-2a signaling is activated in lung tissues of patients with IPAH. Quantitative RT-PCR analysis showed that HIF2A but not HIF1A and HIF-2a downstream genes were upregulated in lung tissues from patients with IPAH compared with healthy donors ( Figure 1A ; see Figure E1A in the online supplement). Immunostaining demonstrated that upregulation of HIF-2a was located mainly in endothelial cells (ECs) of lung sections from patients with IPAH ( Figure 1B ) whereas HIF-1a was in SMCs ( Figure E1B ). Western blotting also showed that HIF-2a protein expression was highly induced in PAECs but not in PASMCs isolated from patients with IPAH ( Figure 1C ).
We next evaluated whether HIF-2a signaling is also induced in rodent models of severe PAH (Sugen 5416/hypoxia [SuHx]-treated rats, monocrotaline [MCT]-challenged rats, and Egln1
Tie2Cre mice [28, 29] ). We observed a marked increase in HIF-2a protein levels and its downstream target genes such as Cxcl12 and Il6 in the lungs of SuHx and MCT rats ( Figures 1D,  1E , E2A, and E2B). Moreover, the expression of many HIF-2a genes was markedly increased in Egln1
Tie2Cre mouse lungs, while attenuated or completely normalized in the lungs of Egln1
Tie2Cre / Hif2a
Tie2Cre double-knockout mice ( Figure  E2C ) but not in Egln1
Tie2Cre /Hif1a
Tie2Cre double-knockout mice (data not shown), demonstrating the reliance of expression of these genes on HIF-2a activation.
Together, these data demonstrate HIF-2a activation in lung tissues of three distinct rodent PAH models, as seen in patients with IPAH.
C76 Represses HIF-2a Activation in Human Lung Microvascular Endothelial Cells
To identify a potent HIF-2a-selective inhibitor in ECs, human lung microvascular ECs (HLMVECs) were transfected with HRE (hypoxia response element)-luciferase reporter plasmid, followed by treatment with H2A (HIF-2a antagonist 2) (30) or the HIF-2a-selective translation inhibitor C76 (31) . Although both H2A and C76 reduced HRE-luciferase activity induced by PHD2 deficiency or DMOG treatment, C76 exhibited a more potent inhibitory effect than H2A (Figures 2A and E3A ). Thus, we further characterized the impact of C76 treatment on HLMVECs. We observed marked inhibition of protein expression of HIF-2a but not HIF-1a in PHD2-deficient ECs and in DMOG-treated ECs after C76 treatment ( Figures 2B and E3B ), along with suppressed expression of HIF-2a target genes ( Figure 2C ). Our previous study demonstrated that one of the mechanisms of HIF-2a activation in PAH is the paracrine effect of dysfunctional ECs on promoting PASMC proliferation (17) . Thus, we determined the effect of C76 on PHD2-deficient EC-induced PASMC proliferation. As shown in Figures 2D, 2E , and E3C, C76 treatment also inhibited the paracrine effect of PHD2-deficient ECs on To assess the potential of targeting HIF-2a signaling for PAH treatment, we treated 3-week-old Egln1 Tie2Cre mice (with established PAH) (17) with C76 for 12 weeks (12.5 mg/kg, i.p., daily). C76 treatment resulted in marked reduction of HIF-2a but not HIF-1a protein levels and expression of HIF-2a downstream targets CXCL12 (C-X-C motif chemokine 12) and ET-1 (endothelin-1) in ECs from Egln1
Tie2Cre mice ( Figures E4A-E4C ), demonstrating the in vivo efficacy of C76 in inhibiting HIF-2a. As shown in Figure 3 , C76 treatment resulted in marked reduction of RVSP ( Figure 3A) and normalization of the PA acceleration time/ejection time (AT/ET) ratio, indicative of preserved PA function in Egln1 Tie2Cre mice ( Figures 3B and 3C ). In addition to hemodynamic improvement, C76 treatment also inhibited obliterative pulmonary vascular remodeling including lack of formation of neointima and vascular occlusive lesions, reduced pulmonary vascular wall thickness, and decreased muscularization of distal PAs ( Figures 3D,  3E , E5A, and E5B). We also observed that C76 treatment reduced abnormal EC proliferation but had no effects on apoptosis in Egln1 Tie2Cre mice ( Figures E5C  and E5D ). Expression of PAH-associated genes such as Cav1, Bmpr2, IL6, and Cxcl12 was normalized in Egln1
Tie2Cre mouse lungs by C76 treatment ( Figure E5E ).
Given that severe PAH results in RV hypertrophy and failure (32), we next evaluated whether C76 treatment could inhibit RHF in Egln1
Tie2Cre mice. As shown in Figure 4A , severe RV hypertrophy seen in Egln1
Tie2Cre mice was markedly inhibited in C76-treated mice versus vehicle controls. Echocardiography showed that RV wall thickness and chamber size were markedly decreased with C76 treatment (Figures 4B,  4C , and E6A). RV fractional area change, indicative of RV contractility, was also drastically improved by C76 treatment ( Figure 4D ). Pathological examination revealed prominent interstitial and perivascular fibrosis in the RV of vehicletreated Egln1
Tie2Cre mice, whereas C76 treatment markedly reduced RV fibrosis (Figures 4E and E6B) . The reactivation of the embryonic gene program seen in heart failure (17, 33) , including induced expression of skeletal a-actin, and atrial natriuretic factor was normalized in C76-treated Egln1 Tie2Cre mice compared with vehicle controls ( Figure  E6C ). These data demonstrated that C76 treatment inhibited RV hypertrophy and failure. Accordingly, all C76-treated mice survived at the end of the 12-week study, whereas 40% of vehicle-treated mice had died within this time period ( Figure 4F ).
HIF-2a Inhibition Reverses Severe PAH and Right Heart Failure in SuHx Rats
Next we sought to determine whether inhibition of HIF-2a could reverse severe PAH in SuHx rats. Rats were administered a single dose of Sugen 5416 and kept in a hypoxia chamber for 3 weeks at 10% O 2 , followed by 3 weeks of normoxia. These rats were then randomly assigned to two groups for treatment with vehicle or C76 for 3 weeks ( Figure 5A ). As shown in Figures E7A-E7C , expression of endothelial HIF-2a and its downstream target genes (also PH-associated genes) including Edn1, Cxcl12, and Il6 was normalized in the lungs of C76-treated SuHx rats. C76 treatment markedly reduced RVSP compared with vehicle ( Figure 5B) , and normalized the PA AT/ET ratio, indicating normalization of PA diastolic function ( Figure 5C ). Pulmonary vascular remodeling, including neointima formation, formation of occlusive lesions, and thickening of the PA wall ( Figures 5D-5F ), as well as muscularization of distal PAs ( Figure E7D ), was markedly inhibited in C76-treated rats compared with vehicle controls, which was likely due to decreased cell proliferation ( Figure E7E ). Together, these data demonstrate that C76 treatment reverses PAH in SuHx rats.
We then assessed the effect of C76 treatment on RV dysfunction in SuHx rats. C76 treatment markedly reduced RV hypertrophy, and RV wall thickness ( Figures  6A and 6B) , and improved RV contractility ( Figure 6C ) in SuHx rats. Fibrosis in the right ventricle was also markedly reduced by C76 treatment ( Figure 6D ). Thus, C76 inhibition of HIF-2a inhibited cardiac fibrosis and preserved RV function in SuHx rats. 
C76 Treatment Inhibits PAH in Monocrotaline-challenged Rats
We also examined the efficacy of C76 treatment in the MCT-induced rat PAH model. Two weeks after MCT challenge, the rats were treated with either C76 or vehicle for another 2 weeks ( Figure 7A ). Expression of endothelial HIF-2a and its downstream target genes was normalized or markedly inhibited in rats treated with C76 compared with vehicle ( Figures E8A and E8B ). C76 treatment inhibited PAH and RV hypertrophy, and restored PA function ( Figures 7B, 7C, and E8C) . Echocardiography also showed that C76 treatment decreased RV wall thickness ( Figure E8D ) and improved RV contractility ( Figure 7D ). Pulmonary vascular remodeling assessed by PA wall thickening, muscularization, and cell proliferation was also markedly attenuated by C76 treatment (Figures E8E  and E8F) . Remarkably, although all rats in the vehicle group had died by Day 28 after a lethal dose of MCT, C76 treatment resulted in a 70% survival rate at that time ( Figure 7G ). Taken together, these data demonstrate that targeting of HIF-2a reversed aberrant vascular remodeling and prevented right heart failure and death in the setting of severe PAH.
Discussion
The present study demonstrates that HIF2a signaling is activated in pulmonary vascular ECs of patients with IPAH and that pharmacological inhibition of HIF-2a is a potential novel therapeutic approach for the effective treatment of PAH, thereby promoting survival. In Egln1
Tie2Cre mice, C76 treatment inhibited obliterative pulmonary vascular remodeling including neointima formation and occlusive vascular lesions, reduced RV hypertrophy and cardiac fibrosis, inhibited RVF, and promoted survival. In SuHx rats, C76 treatment reversed pulmonary vascular remodeling, inhibited RV hypertrophy and cardiac fibrosis, and preserved cardiac function. Similarly, RVSP, pulmonary vascular remodeling, and RV hypertrophy as well as the mortality rate were markedly reduced in C76-treated MCT rats. The beneficial impact of inhibiting HIF-2a is particularly encouraging in a translational context, given that selective HIF-2a inhibitors have already been tested in phase 1 clinical trials in patients with renal cancer (34, 35) .
The rodent models of PAH employed in our study represent a range of PAHinducing stimuli and complement each other, and thereby provide important information about the translational potential of HIF-2a inhibition in the treatment of PAH. MCT-induced PAH in rats results from pulmonary accumulation of pyrrolic metabolites leading to endothelial injury and modest remodeling of the pulmonary vasculature (36, 37) . SuHx-induced PAH in rats results from inhibition of the vascular endothelial growth factor (VEGF) receptors under hypoxic conditions, leading to the formation of plexiform lesions and neointima (28, 38) . In the Egln1 Tie2Cre mouse model, PAH results from genetic deletion of PHD2 in endothelial and hematopoietic cells, culminating in severe vascular occlusion, the formation of plexiform-like lesions, RV hypertrophy and failure, and progressive mortality (17) . Although any individual rodent model of PAH is unlikely to fully replicate the pathogenesis of human PAH, our study certainly demonstrates that HIF-2a inhibition reverses PAH in three mechanistically different rodent models of PAH.
Although endothelial deletion of HIF2a induces minor PH in mice at late ages (39) , studies highlight the crucial role of HIF-2a activation in the pathogenesis of PAH (14) (15) (16) (17) (18) (19) 22) , especially in regulating obliterative pulmonary vascular remodeling and RHF (17, 21, 22 of the potent vasoconstrictor, endothelin-1 (Edn1), in the lungs of PHD2-deficient mice (17, 18) . Cowburn and colleagues showed that increased endothelial arginase expression via HIF-2a activation disturbed normal nitric oxide homeostasis in vivo, which resulted in hypoxic pulmonary vasoconstriction (19) . Thrombospondin-1, another HIF-2a target, was shown to increase fibroblast and SMC migration, recruit circulating monocytes, and contribute to hypoxic vascular remodeling and PAH (40, 42) . Transgenic mice overexpressing IL-6, which is also a HIF-2a downstream target, exhibit occlusive vascular remodeling (43, 44) . In addition, PHD2-deficient ECs induce PASMC proliferation through angiogenic paracrine factors including CXCL12, a specific HIF-2a target gene, in lung ECs (17, 45) .
Moreover, Tang and colleagues demonstrated that endothelial HIF-2a mediated endothelial mesenchymal transition via upregulation of downstream target SNAIL1/2 (22) . Collectively, a broad dysregulation of multiple signaling pathways secondary to HIF-2a activation contributes to a progressive increase in pulmonary vascular resistance and severe pulmonary vascular remodeling in PAH. The protective impact of HIF-2a inhibition observed in our study could be attributed to normalized expression of these and other PAH-inducing genes such as Il6, Cxcl12, Edn1, Cav1, and Bmpr2. In other words, it is plausible that HIF-2a inhibitors could act through a number of different downstream targets of HIF-2a, which would otherwise facilitate the progression of PAH through parallel or divergent signaling pathways.
Thus, targeting HIF-2a has great translational potential in reversing pulmonary vascular remodeling and normalizing vascular pulmonary homeostasis in PAH.
The HIF-2a inhibitor used in this study, C76, selectively decreases HIF-2a translation by enhancing the binding of IRP1 (iron-regulatory protein 1) to the 59-untranslated region of HIF2A, but not HIF1A (31). Our in vitro and in vivo studies also demonstrate the selectivity of C76 in lung ECs. C76 treatment results in inhibition of HIF-2a expression but not HIF-1a in human lung ECs. We also observed in vivo inhibition of HIF-2a expression and its target genes in lungs from the three rodent PAH models. HIF-1a expression in lung ECs was not inhibited by C76 treatment in Egln1
Tie2Cre mice. Thus, the in vivo effects of C76 in inhibiting PAH are likely attributable to selective HIF-2a targeting. In addition, other small molecules targeting HIF-2-ARNT (aryl hydrocarbon receptor nuclear translocator) heterodimerization have been developed, which have been tested in phase 1 clinical trials in patients with renal cancer (34, 35) . It would be pertinent to determine whether this class of HIF-2a inhibitors also inhibits PAH.
As HIF-1a and HIF-2a share high sequence homology and similar O 2 -dependent regulation, several compounds have been shown to inhibit the transcriptional activities of both HIF-1a and HIF-2a. Zhang and colleagues have reported that cardiac glycosides including digoxin inhibit both HIF-1a and HIF-2a protein synthesis but with lower inhibitory activity toward HIF-2a than HIF-1a (46) . Acriflavine, a chromophore with antibacterial activities, was demonstrated to bind to the PAS-B domain of HIF-1a and HIF-2a and inhibit HIF dimerization and transcriptional activity (47) . Both digoxin and acriflavine treatment limits RVSP elevation and RV hypertrophy in hypoxiatreated mice (48) . Although these published studies indicate that HIF-1a inhibition mediates the in vivo effects, it is likely that HIF-2a inhibition by these compounds plays a determinant role in inhibiting PH.
In addition to ECs, HIF-2a is also expressed in alveolar epithelial cells and fibroblasts (49, 50) . Although previous studies showed that both HIF-1a and HIF-2a inhibition on Postnatal Day 4 in mice impaired alveolar development, C76 treatment did not affect the mean linear intercept of alveoli in adult Egln1 Tie2Cre mice ( Figure E9A ). Other report also showed that pulmonary fibroblast HIF-2a mediated hypoxia-induced fibroblast proliferation (50) . It is likely that inhibited adventitial formation in C76-treated Egln1
Tie2Cre mouse lungs is attributable to C76-inhibited fibroblast proliferation. Future studies are warranted to address this possibility. In addition, C76 may directly act on SMC HIF-2a and thereby inhibit pulmonary vascular remodeling. However, previous studies by Tang and colleagues demonstrated that HIF2a
Myh11Cre mice were not protected from hypoxia-induced PH, suggesting that SMC HIF-2a is not involved in the development of PH in mice (22) . Our Egln1 Tie2Cre /HIF2a Tie2Cre mice exhibited a normal pulmonary phenotype, demonstrating the importance of EC HIF-2a (17) . Here we show that C76 did not affect the proliferation and apoptosis of PASMCs isolated from patients with IPAH ( Figures E3D and E3E ), indicating that C76 has no direct effects on SMCs. Importantly, C76 treatment did not affect heart rate, body weight, and plasma erythropoietin levels in both Egln1
Tie2Cre mice and SuHxexposed rats (Figures E9B-E9D ). These data suggest that targeting HIF-2a is potentially safe.
Collectively, our findings unveil the potential of targeting HIF-2a for effective treatment of PAH in patients and for promotion of survival, and provide convincing support for the development of novel and specific HIF-2a inhibitors that aim to reverse pulmonary vascular remodeling, inhibit RHF, and promote survival. n 
